Neurocrine biosciences initiates phase 3 registrational program for nbi-1117568 as potential treatment for adults with schizophrenia

San diego , april 30, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced the initiation of a phase 3 registrational program to evaluate the efficacy, safety and tolerability of nbi-1117568, the company's investigational oral muscarinic m4 selective orthosteric agonist, as a potential treatment for schizophrenia. positive top-line data for the phase 2 clinical study in adults with schizophrenia were reported in august 2024.
NBIX Ratings Summary
NBIX Quant Ranking